NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 232)
Posted On: 02/26/2020 1:50:39 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach
Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all without subjecting cancer patients to aggressive, potentially ineffective drugs. The cancer cells are tricked into thinking they’re still multiplying inside the patient, which makes the tumor behave as it would normally — revealing more precise cancer biomarkers. TumorGenesis’ unique research approach benefits from the parent company’s enormous database of tumor drug-response profiles and artificial intelligence-driven predictive modeling capabilities. . . . TumorGenesis has developed its proprietary methodology using PDx to culture tumor cells in vivo (i.e. in living organisms). These cell models can be then tested repeatedly for various new drugs to establish personalized therapeutics. This patient-specific data is revolutionizing the way cancer is treated today, and POAI, through its strategic subsidiary arms, poses an attractive option for investors looking to invest in the cancer treatment of tomorrow.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all without subjecting cancer patients to aggressive, potentially ineffective drugs. The cancer cells are tricked into thinking they’re still multiplying inside the patient, which makes the tumor behave as it would normally — revealing more precise cancer biomarkers. TumorGenesis’ unique research approach benefits from the parent company’s enormous database of tumor drug-response profiles and artificial intelligence-driven predictive modeling capabilities. . . . TumorGenesis has developed its proprietary methodology using PDx to culture tumor cells in vivo (i.e. in living organisms). These cell models can be then tested repeatedly for various new drugs to establish personalized therapeutics. This patient-specific data is revolutionizing the way cancer is treated today, and POAI, through its strategic subsidiary arms, poses an attractive option for investors looking to invest in the cancer treatment of tomorrow.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)